Cleared Traditional

K864524 - SPERM SELECT(TM)

K864524 is the FDA 510(k) clearance for SPERM SELECT(TM) by Pharmacia, Inc.. It is a Class 2 Pathology device (product code MQL) cleared through the Traditional 510(k) pathway after a 77-day FDA review.

K864524 · Pharmacia, Inc. · Pathology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1987
Decision
77d
Days
Class 2
Risk

K864524 is an FDA 510(k) clearance for the SPERM SELECT(TM). Classified as Media, Reproductive (product code MQL), Class II - Special Controls.

Submitted by Pharmacia, Inc. (Piscataway, US). The FDA issued a Cleared decision on February 2, 1987 after a review of 77 days - a notably fast clearance cycle.

This device falls under the Pathology FDA review panel, regulated under 21 CFR 884.6180 - the FDA pathology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Pharmacia, Inc. devices

Submission Details

510(k) Number K864524 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 17, 1986
Decision Date February 02, 1987
Days to Decision 77 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
At panel average
Panel avg: 77d · This submission: 77d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code MQL Media, Reproductive
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 884.6180
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Pathology devices follow this clearance model.